- Trials with a EudraCT protocol (54)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (8)
54 result(s) found for: Developmental Disorder.
Displaying page 1 of 3.
EudraCT Number: 2016-002875-81 | Sponsor Protocol Number: NL58621.041.16 | Start Date*: 2016-10-19 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:UMC Utrecht | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Bumetanide for the Autism Spectrum Clinical Effectiveness Trial | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Epilepsy | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001630-33 | Sponsor Protocol Number: MEM-MD-69 | Start Date*: 2012-11-14 | |||||||||||||||||||||
Sponsor Name:Forest Research Institute, Inc | |||||||||||||||||||||||
Full Title: An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients with Autism, Asperger’s Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) | |||||||||||||||||||||||
Medical condition: Autism or Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated with Memantine | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed) NL (Ongoing) EE (Completed) FR (Ongoing) IS (Prematurely Ended) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-005346-37 | Sponsor Protocol Number: F1D-MC-HGMR | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Eli Lilly and Company Limited | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Maintenance of Effect Study of Olanzapine in the Treatment of Disruptive Behavioral Symptoms in Children and Adolescents with Pervasive Developmental ... | |||||||||||||
Medical condition: children and adolescents with disruptive behavioral symptoms associated with Pervasive Developmental Disorders (PDD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001568-31 | Sponsor Protocol Number: MEM-MD-68 | Start Date*: 2012-11-14 | |||||||||||||||||||||
Sponsor Name:Forest Research Institute, Inc | |||||||||||||||||||||||
Full Title: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients with Autism, Asperger’s Disorder, or Pervasive Developmental Disorder ... | |||||||||||||||||||||||
Medical condition: Autism or Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated with Memantine | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed) NL (Ongoing) EE (Completed) FR (Ongoing) IT (Completed) IS (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-001616-33 | Sponsor Protocol Number: MEM-MD-91 | Start Date*: 2012-11-14 | |||||||||||||||||||||
Sponsor Name:Forest Research Institute, Inc. | |||||||||||||||||||||||
Full Title: An Open-Label Study Of The Safety And Tolerability Of Memantine In Pediatric Patients With Autism, Asperger’s Disorder, Or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) | |||||||||||||||||||||||
Medical condition: Autism or Asperger’s Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed) NL (Ongoing) EE (Completed) IS (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004378-32 | Sponsor Protocol Number: WN39434 | Start Date*: 2018-09-26 | |||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||
Full Title: A phase III, randomized, double-blind, placebo-controlled, efficacy, and safety study of Balovaptan in adults with Autism Spectrum Disorder with a 2 year open-label extension. | |||||||||||||||||||||||
Medical condition: Autism Spectrum Disorder | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) ES (Completed) FR (Completed) IT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-001909-25 | Sponsor Protocol Number: | Start Date*: Information not available in EudraCT |
Sponsor Name: | ||
Full Title: Effekter av behandling med atomoxetine ved komorbid ADHD hos pasienter med Pervasive Developmental Disorders (Effects of treatment with atomoxetine in children with Pervasive Developmental Disorder... | ||
Medical condition: Open treatment with atomoxetine for 10 weeks: •Week 1: 0,5 mg/kg/day in 1 or 2 doses. •Week 2 – 6: 1,2 mg/kg/day i 1 or 2 doses. •Week 6 – 8: Significant improvements: Continue on 1,2 mg/kg/day in ... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002196-35 | Sponsor Protocol Number: 73520 | Start Date*: 2020-11-16 |
Sponsor Name:Amsterdam UMC, location VUmc | ||
Full Title: post-trial access cohort BUmetanide for Developmental DIsorders | ||
Medical condition: Neurodevelopmental disorders Autism spectrum disorder Attention deficit hyperactivity disorder (ADHD) Learning disorders | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004025-28 | Sponsor Protocol Number: HTA 05-14-02 | Start Date*: 2007-06-26 | ||||||||||||||||
Sponsor Name:Royal Liverpool Children’s NHS Trust | ||||||||||||||||||
Full Title: MENDS: The use of MElatonin in children with Neuro-developmental Disorders and impaired Sleep; a randomised, double-blind, placebo-controlled, parallel study | ||||||||||||||||||
Medical condition: children with neuro-developmental disorders and impaired sleep | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001109-22 | Sponsor Protocol Number: PBGM01-001 | Start Date*: Information not available in EudraCT |
Sponsor Name:Passage Bio, Inc. | ||
Full Title: A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Su... | ||
Medical condition: GM1 gangliosidosis (GM1) is an autosomal recessive disorder that results from mutations in the human galactosidase beta 1 gene (GLB1), which encodes beta-galactosidase (β-gal). | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001523-39 | Sponsor Protocol Number: D1050300 | Start Date*: 2013-11-08 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A PHASE 1 OPEN-LABEL, MULTICENTER, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF LURASIDONE IN SUBJECTS 6 TO 17 YEARS OLD WITH SCHIZOPHRENIA SPE... | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011887-12 | Sponsor Protocol Number: ADHS_Koenig | Start Date*: 2009-10-14 |
Sponsor Name:Praxis Prof. Koenig | ||
Full Title: Evaluation of ADHD from childhood to adolescence- impact of medical treatment on autonomic nervous system parameters | ||
Medical condition: ADHD is a neurobehavioral developmental disorder which affects about 5% of children. In our clinical trial designed we would like to examine whether medical treatment with stimulants has an influen... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-006444-21 | Sponsor Protocol Number: EC07/90076 | Start Date*: 2009-02-13 | |||||||||||
Sponsor Name:Fundación para la Investigación Biomédica Hospital Gregorio Marañón | |||||||||||||
Full Title: EFFECT OF 8-WEEK FATTY ACIDS OMEGA-3 TREATMENT ON OXIDATIVE METABOLISM IN PATIENTS WITH AUTISM SPECTRUM DISORDER: A RANDOMISED DOUBLE-BLIND CROSSOVER PLACEBO-CONTROLLED TRIAL. | |||||||||||||
Medical condition: autism spectrum disorders Trastornos del Espectro Autista | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000304-16 | Sponsor Protocol Number: B4Z-UT-S017 | Start Date*: 2021-12-02 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder. | |||||||||||||
Medical condition: Attention-Deficit/Hyperactivity Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000788-27 | Sponsor Protocol Number: RD01273 | Start Date*: 2006-04-20 |
Sponsor Name:Royal United Hospital Bath NHS Trust | ||
Full Title: International Collaborative Infantile Spasms Study (ICISS) | ||
Medical condition: Infantile spasms are a rare severe form of epilepsy affecting approx 1 in 2,250 infants, usually under the age of 1 year. Affected infants have a very abnormal EEG and a poor prognosis for subseque... | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001694-24 | Sponsor Protocol Number: D1050302 | Start Date*: 2014-03-11 | |||||||||||
Sponsor Name:SUNOVION PHARMACEUTICALS INC. | |||||||||||||
Full Title: A 104-WEEK, FLEXIBLE-DOSE, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN PEDIATRIC SUBJECTS WITH SCHIZOPHRENIA AND SUBJECTS WITH IRRIT... | |||||||||||||
Medical condition: SCHIZOPHRENIA AND IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Prematurely Ended) BG (Completed) Outside EU/EEA HU (Completed) GB (Completed) DE (Completed) PL (Completed) BE (Completed) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000586-45 | Sponsor Protocol Number: S56327 | Start Date*: 2014-05-08 | |||||||||||
Sponsor Name:KU Leuven | |||||||||||||
Full Title: Oxytocin-based pharmacotherapy for Autism Spectrum Disorders: Investigating the neural and behavioral effects of a promising intervention approach | |||||||||||||
Medical condition: Young male adults with Autism Spectrum Disorders (18-30 years) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000565-40 | Sponsor Protocol Number: GLM101-002 | Start Date*: 2022-11-04 | |||||||||||
Sponsor Name:Glycomine, Inc | |||||||||||||
Full Title: A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participa... | |||||||||||||
Medical condition: PMM2-CDG | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001320-31 | Sponsor Protocol Number: RIS-AUT-JPN-01 | Start Date*: 2015-03-27 | |||||||||||
Sponsor Name:Janssen Pharmaceutical K.K | |||||||||||||
Full Title: A Double-blind, Placebo-controlled Study, Followed by an Open-label Extension Study Evaluating the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents with Irritability Associa... | |||||||||||||
Medical condition: Autistic disorder in children and adolescents | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002485-39 | Sponsor Protocol Number: TAK-935-18-001(OV935)Amendment1 | Start Date*: 2019-06-14 |
Sponsor Name:Ovid Therapeutics, Inc. | ||
Full Title: A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEP... | ||
Medical condition: developmental and epileptic encephalopathies | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) PL (Trial now transitioned) PT (Trial now transitioned) Outside EU/EEA | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.